WO2007081630A3 - Substituted pyrimidinyl kinase inhibitors - Google Patents

Substituted pyrimidinyl kinase inhibitors Download PDF

Info

Publication number
WO2007081630A3
WO2007081630A3 PCT/US2006/061890 US2006061890W WO2007081630A3 WO 2007081630 A3 WO2007081630 A3 WO 2007081630A3 US 2006061890 W US2006061890 W US 2006061890W WO 2007081630 A3 WO2007081630 A3 WO 2007081630A3
Authority
WO
WIPO (PCT)
Prior art keywords
kinase inhibitors
substituted pyrimidinyl
substituted
ameliorating
disorder
Prior art date
Application number
PCT/US2006/061890
Other languages
French (fr)
Other versions
WO2007081630A2 (en
Inventor
Guozhang Xu
Lily Lee
Peter J Connolly
Steven A Middleton
Stuart L Emanuel
Terry V Hughes
Marta C Abad
Prabha S Karnachi
Steven K Wetter
Original Assignee
Janssen Pharmaceutica Nv
Guozhang Xu
Lily Lee
Peter J Connolly
Steven A Middleton
Stuart L Emanuel
Terry V Hughes
Marta C Abad
Prabha S Karnachi
Steven K Wetter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Guozhang Xu, Lily Lee, Peter J Connolly, Steven A Middleton, Stuart L Emanuel, Terry V Hughes, Marta C Abad, Prabha S Karnachi, Steven K Wetter filed Critical Janssen Pharmaceutica Nv
Publication of WO2007081630A2 publication Critical patent/WO2007081630A2/en
Publication of WO2007081630A3 publication Critical patent/WO2007081630A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
PCT/US2006/061890 2005-12-21 2006-12-12 Substituted pyrimidinyl kinase inhibitors WO2007081630A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75263305P 2005-12-21 2005-12-21
US60/752,633 2005-12-21

Publications (2)

Publication Number Publication Date
WO2007081630A2 WO2007081630A2 (en) 2007-07-19
WO2007081630A3 true WO2007081630A3 (en) 2007-12-21

Family

ID=38256842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/061890 WO2007081630A2 (en) 2005-12-21 2006-12-12 Substituted pyrimidinyl kinase inhibitors

Country Status (3)

Country Link
AR (1) AR058624A1 (en)
TW (1) TW200800919A (en)
WO (1) WO2007081630A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US7982036B2 (en) 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
WO2009055299A1 (en) * 2007-10-23 2009-04-30 Janssen Pharmaceutica N.V. Substituted pyrimidine-5-carboxamide and 5-carboxylic ester kinase inhibitors
JP5918264B2 (en) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Hepatitis C inhibitor and use thereof
JP5965923B2 (en) * 2011-02-24 2016-08-10 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド Phosphorus-containing compounds as protein kinase inhibitors
CA2829755A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
CN103058935B (en) * 2013-01-15 2015-05-06 四川大学 Pyrimidine compound as well as preparation method and use for same
CN112500338A (en) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
AR096654A1 (en) * 2013-06-20 2016-01-27 Ab Science DERIVATIVES OF BENZIMIDAZOL AS SELECTIVE INHIBITORS OF PROTEIN QUINASA
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
CN104744446B (en) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 Heteroaryl compound and its application in drug
US9840474B2 (en) 2014-04-24 2017-12-12 Sichuan University Pyrimidine compounds and use as anti-cervical cancer thereof
AU2019255310B2 (en) 2018-04-18 2022-11-24 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2021038419A1 (en) * 2019-08-23 2021-03-04 Insilico Medicine Ip Limited Kinase inhibitors and methods of synthesis and treatment
TWI750905B (en) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 Thiazole compounds as protein kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030060466A1 (en) * 2001-06-01 2003-03-27 Alfred Binggeli Pyrimidine, pyrazine and triazine derivatives
US20030139435A1 (en) * 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
US20050261313A1 (en) * 2001-01-12 2005-11-24 Amgen Inc. Substituted alkylamine derivatives and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261313A1 (en) * 2001-01-12 2005-11-24 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030060466A1 (en) * 2001-06-01 2003-03-27 Alfred Binggeli Pyrimidine, pyrazine and triazine derivatives
US20030139435A1 (en) * 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression

Also Published As

Publication number Publication date
TW200800919A (en) 2008-01-01
WO2007081630A2 (en) 2007-07-19
AR058624A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
WO2007081630A3 (en) Substituted pyrimidinyl kinase inhibitors
WO2007109783A3 (en) Substituted pyrimidine kinase inhibitors
WO2007092879A3 (en) Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
WO2007084815A3 (en) Substituted thienopyrimidine kinase inhibitors
WO2007121154A3 (en) Substituted benzothiazole kinase inhibitors
WO2007049041A8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
MY139689A (en) Imidazotriazines as protein kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2008059368A3 (en) Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2007056163A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
WO2007059257A3 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
ATE525375T1 (en) INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1
WO2007079164A3 (en) Protein kinase inhibitors
WO2007027238A3 (en) Jak kinase inhibitors and their uses
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2008006547A3 (en) Pyrrolopyrimidines for pharmaceutical compositions
WO2006047503A3 (en) Inhibitors of c-fms kinase
WO2007041130A3 (en) Deazapurines useful as inhibitors of janus kinases
WO2007047646A3 (en) Substituted dihydro-isoindolones useful in treating kinase disorders
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06849207

Country of ref document: EP

Kind code of ref document: A2